Advertisement

Neurotoxicity Research

, Volume 36, Issue 4, pp 724–735 | Cite as

Diffusion Kurtosis Imaging Detects Microstructural Changes in a Methamphetamine-Induced Mouse Model of Parkinson’s Disease

  • Anas Arab
  • Jana Ruda-KucerovaEmail author
  • Alzbeta Minsterova
  • Eva Drazanova
  • Nikoletta Szabó
  • Zenon StarcukJr
  • Irena Rektorova
  • Amit Khairnar
Original Article

Abstract

Methamphetamine (METH) abuse is known to increase the risk of Parkinson’s disease (PD) due to its dopaminergic neurotoxicity. This is the rationale for the METH model of PD developed by toxic METH dosing (10 mg/kg four times every 2 h) which features robust neurodegeneration and typical motor impairment in mice. In this study, we used diffusion kurtosis imaging to reveal microstructural brain changes caused by METH-induced neurodegeneration. The METH-treated mice and saline-treated controls underwent diffusion kurtosis imaging scanning using the Bruker Avance 9.4 Tesla MRI system at two time-points: 5 days and 1 month to capture both early and late changes induced by METH. At 5 days, we found a decrease in kurtosis in substantia nigra, striatum and sensorimotor cortex, which is likely to indicate loss of DAergic neurons. At 1 month, we found an increase of kurtosis in striatum and sensorimotor cortex and hippocampus, which may reflect certain recovery processes. Furthermore, we performed tract-based spatial statistics analysis in the white matter and at 1 month, we observed increased kurtosis in ventral nucleus of the lateral lemniscus and some of the lateral thalamic nuclei. No changes were present at the early stage. This study confirms the ability of diffusion kurtosis imaging to detect microstructural pathological processes in both grey and white matter in the METH model of PD. The exact mechanisms underlying the kurtosis changes remain to be elucidated but kurtosis seems to be a valuable biomarker for tracking microstructural brain changes in PD and potentially other neurodegenerative disorders.

Keywords

Behaviour Diffusion kurtosis imaging Methamphetamine Mice MRI Parkinson’s disease Tract-based spatial statistics 

Notes

Acknowledgments

The authors are grateful to Dr. Peter Latta for his valuable technical support and help with the MRI scanning and a professional data analyst Ms. Daniela Kuruczova for her advice on statistical analysis. The behavioural apparatuses for the challenging beam traversal and grid test were kindly provided by Jiri Kucera, Environmental Measuring Systems, Brno, Czech Republic.

Funding

This study was performed at Masaryk University as part of the project “Pharmacological research in the field of pharmacokinetics, neuropsychopharmacology and oncology”, number MUNI/A/1550/2018, with the support of the Specific University Research Grant, as provided by the Ministry of Education, Youth and Sports of the Czech Republic in the year 2019 and also supported by funds from the Faculty of Medicine MU to junior researcher Jana Ruda-Kucerova. The work was also supported from European Regional Development Fund-Project “National infrastructure for biological and medical imaging” (No. CZ.02.1.01/0.0/0.0/16_013/0001775). We acknowledge the core facility MAFIL of CEITEC and the MR unit and the animal facility (CZ62760225) of ISI CAS, both supported by the Czech-BioImaging large RI project (LM2015062 funded by MEYS CR), for their support with obtaining scientific data presented in this paper. Nikoletta Szabo was supported by NAP 2.0 (2017-1.2.1-NKP-2017-00002), EFOP-3.6.1-16-2016-00008 and KTIA_13_NAP-A-II/20. The ISI CAS support was further co-financed by MEYS CR and EC (CZ.1.05/2.1.00/01.0017) and by the CAS (RVO:68081731).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. Achat-Mendes C, Ali SF, Itzhak Y (2005) Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice. Neuropsychopharmacology 30(6):1128–1137PubMedGoogle Scholar
  2. Alexander AL, Hasan K, Kindlmann G, Parker DL, Tsuruda JS (2000) A geometric analysis of diffusion tensor measurements of the human brain. Magn Reson Med 44(2):283–291PubMedGoogle Scholar
  3. Alexander AL, Lee JE, Lazar M, Field AS (2007) Diffusion tensor imaging of the brain. Neurotherapeutics 4(3):316–329PubMedPubMedCentralGoogle Scholar
  4. Arab A, Wojna-Pelczar A, Khairnar A, Szabó N, Ruda-Kucerova J (2018) Principles of diffusion kurtosis imaging and its role in early diagnosis of neurodegenerative disorders. Brain Res Bull 139:91–98PubMedGoogle Scholar
  5. Ares-Santos S, Granado N, Oliva I, O'Shea E, Martin ED, Colado MI, Moratalla R (2012) Dopamine D (1) receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol Dis 45(2):810–820PubMedGoogle Scholar
  6. Basser PJ (1995) Inferring microstructural features and the physiological state of tissues from diffusion-weighted images. NMR Biomed 8(7–8):333–344PubMedGoogle Scholar
  7. Basser PJ (1997) New histological and physiological stains derived from diffusion-tensor MR images. Ann N Y Acad Sci 820:123–138PubMedGoogle Scholar
  8. Berman S, O’Neill J, Fears S, Bartzokis G, London ED (2008) Abuse of amphetamines and structural abnormalities in the brain. Ann N Y Acad Sci 1141:195–220PubMedPubMedCentralGoogle Scholar
  9. Bowyer JF, Thomas M, Schmued LC, Ali SF (2008) Brain region-specific neurodegenerative profiles showing the relative importance of amphetamine dose, hyperthermia, seizures, and the blood-brain barrier. Ann N Y Acad Sci 1139:127–139PubMedGoogle Scholar
  10. Cadet JL, Jayanthi S, Deng X (2005) Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review. Neurotox Res 8(3–4):199–206PubMedGoogle Scholar
  11. Chaudhuri KR, Martinez-Martin P (2008) Quantitation of non-motor symptoms in Parkinson’s disease. Eur J Neurol 15(Suppl 2):2–7PubMedGoogle Scholar
  12. Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR (2012) A progressive mouse model of Parkinson’s disease: the Thy1-aSyn (“line 61”) mice. Neurotherapeutics 9(2):297–314PubMedPubMedCentralGoogle Scholar
  13. Chuhutin A, Hansen B, Jespersen SN (2017) Precision and accuracy of diffusion kurtosis estimation and the influence of b-value selection. NMR Biomed 30(11):e3777Google Scholar
  14. Commins DL, Seiden LS (1986) Alpha-methyltyrosine blocks methylamphetamine-induced degeneration in the rat somatosensory cortex. Brain Res 365(1):15–20PubMedGoogle Scholar
  15. Costa A, Caltagirone C (2015) Individual differences in approach-avoidance aptitude: some clues from research on Parkinson’s disease. Front Syst Neurosci 9:43PubMedPubMedCentralGoogle Scholar
  16. Csete G, Szabo N et al (2014) An investigation of the white matter microstructure in motion detection using diffusion MRI. Brain Res 1570:35–42PubMedGoogle Scholar
  17. Cunha-Oliveira T, Rego AC, Oliveira CR (2008) Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res Rev 58(1):192–208PubMedGoogle Scholar
  18. Delenclos M, Carrascal L, Jensen K, Romero-Ramos M (2014) Immunolocalization of human alpha-Synuclein in the Thy1-aSyn (“line 61”) transgenic mouse line. Neuroscience 277:647–664PubMedGoogle Scholar
  19. Fantegrossi WE, Ciullo JR, Wakabayashi KT, de la Garza R II, Traynor JR, Woods JH (2008) A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 151(2):533–543PubMedGoogle Scholar
  20. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR (1997) Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 282(2):834–838PubMedGoogle Scholar
  21. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-Synuclein. J Neurosci 24(42):9434–9440PubMedPubMedCentralGoogle Scholar
  22. Fleming SM, Salcedo J, Hutson CB, Rockenstein E, Masliah E, Levine MS, Chesselet MF (2006) Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-Synuclein. Neuroscience 142(4):1245–1253PubMedPubMedCentralGoogle Scholar
  23. Fornai F, Lenzi P, Ferrucci M, Lazzeri G, Poggio AB, Natale G, Busceti CL, Biagioni F, Giusiani M, Ruggieri S, Paparelli A (2005) Occurrence of neuronal inclusions combined with increased nigral expression of alpha-Synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res Bull 65(5):405–413PubMedGoogle Scholar
  24. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4:47PubMedPubMedCentralGoogle Scholar
  25. Franklin, K. B. J. and G. Paxinos (2013). Paxinos and Franklin’s the mouse brain in stereotaxic coordinatesGoogle Scholar
  26. Granado N, Ares-Santos S, O’Shea E, Vicario-Abejón C, Colado MI, Moratalla R (2010) Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: early loss of TH in striosomes after methamphetamine. Neurotox Res 18(1):48–58PubMedGoogle Scholar
  27. Granado N, Ares-Santos S et al (2013) Methamphetamine and Parkinson’s disease. Parkinsons Dis 2013:308052PubMedPubMedCentralGoogle Scholar
  28. Hansen B, Jespersen SN (2017) Recent developments in fast kurtosis imaging. Front Phys 5(40)Google Scholar
  29. Harvey DC, Lacan G, Tanious SP, Melega WP (2000) Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 871(2):259–270PubMedGoogle Scholar
  30. Hsieh JH, Stein DJ et al (2014) The neurobiology of methamphetamine induced psychosis. Front Hum Neurosci 8:537PubMedPubMedCentralGoogle Scholar
  31. Jenkinson, M., Smith, S., 2001. A global optimisation method for robust affineregistration of brain images. Med. Image Anal. 5, 143–156.PubMedGoogle Scholar
  32. Jensen JH, Helpern JA (2010) MRI quantification of non-Gaussian water diffusion by kurtosis analysis. NMR Biomed 23(7):698–710PubMedPubMedCentralGoogle Scholar
  33. Jiang W, Li J, Zhang Z, Wang H, Wang Z (2014) Epigenetic upregulation of alpha-Synuclein in the rats exposed to methamphetamine. Eur J Pharmacol 745:243–248PubMedGoogle Scholar
  34. Kamagata K, Tomiyama H, Hatano T, Motoi Y, Abe O, Shimoji K, Kamiya K, Suzuki M, Hori M, Yoshida M, Hattori N, Aoki S (2014) A preliminary diffusional kurtosis imaging study of Parkinson disease: comparison with conventional diffusion tensor imaging. Neuroradiology 56(3):251–258PubMedGoogle Scholar
  35. Kamagata, K., A. Zalesky, et al. (2017). "Gray matter abnormalities in idiopathic Parkinson’s disease: evaluation by diffusional kurtosis imaging and neurite orientation dispersion and density imaging." Hum Brain MappGoogle Scholar
  36. Khairnar A, Latta P, Drazanova E, Ruda-Kucerova J, Szabó N, Arab A, Hutter-Paier B, Havas D, Windisch M, Sulcova A, Starcuk Z, Rektorova I (2015) Diffusion kurtosis imaging detects microstructural alterations in brain of alpha-Synuclein overexpressing transgenic mouse model of Parkinson’s disease: a pilot study. Neurotox Res 28(4):281–289PubMedGoogle Scholar
  37. Khairnar A, Ruda-Kucerova J, Drazanova E, Szabó N, Latta P, Arab A, Hutter-Paier B, Havas D, Windisch M, Sulcova A, Starcuk Z Jr, Király A, Rektorova I (2016) Late-stage alpha-Synuclein accumulation in TNWT-61 mouse model of Parkinson’s disease detected by diffusion kurtosis imaging. J Neurochem 136(6):1259–1269PubMedGoogle Scholar
  38. Khairnar A, Ruda-Kucerova J, Szabó N, Drazanova E, Arab A, Hutter-Paier B, Neddens J, Latta P, Starcuk Z Jr, Rektorova I (2017) Early and progressive microstructural brain changes in mice overexpressing human alpha-Synuclein detected by diffusion kurtosis imaging. Brain Behav Immun 61:197–208PubMedGoogle Scholar
  39. Khan AR, Chuhutin A, Wiborg O, Kroenke CD, Nyengaard JR, Hansen B, Jespersen SN (2016) Biophysical modeling of high field diffusion MRI demonstrates micro-structural aberration in chronic mild stress rat brain. Neuroimage 142:421–430PubMedPubMedCentralGoogle Scholar
  40. Knossalla F, Kohl Z, Winkler J, Schwab S, Schenk T, Engelhorn T, Doerfler A, Gölitz P (2018) High-resolution diffusion tensor-imaging indicates asymmetric microstructural disorganization within substantia nigra in early Parkinson’s disease. J Clin Neurosci 50:199–202PubMedGoogle Scholar
  41. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19(8):312–318PubMedGoogle Scholar
  42. Kuehn BM (2011) Meth use linked to risk of Parkinson disease. JAMA 306(8):814PubMedGoogle Scholar
  43. Lappin JM, Darke S, Farrell M (2018) Methamphetamine use and future risk for Parkinson’s disease: evidence and clinical implications. Drug Alcohol Depend 187:134–140PubMedGoogle Scholar
  44. Leemans A, Jones DK (2009) The B-matrix must be rotated when correcting for subject motion in DTI data. Magn Reson Med 61(6):1336–1349PubMedGoogle Scholar
  45. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, Shinn AK, Miotto K, Learn J, Dong Y, Matochik JA, Kurian V, Newton T, Woods R, Rawson R, Ling W (2004) Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61(1):73–84PubMedGoogle Scholar
  46. Moratalla R, Khairnar A, Simola N, Granado N, García-Montes JR, Porceddu PF, Tizabi Y, Costa G, Morelli M (2017) Amphetamine-related drugs neurotoxicity in humans and in experimental animals: main mechanisms. Prog Neurobiol 155:149–170PubMedGoogle Scholar
  47. Natale G, Kastsiuchenka O, Pasquali L, Ruggieri S, Paparelli A, Fornai F (2008) MPTP- but not methamphetamine-induced parkinsonism extends to catecholamine neurons in the gut. Ann N Y Acad Sci 1139:345–349PubMedGoogle Scholar
  48. Pan MH, Lai CS, Ho CT (2010) Anti-inflammatory activity of natural dietary flavonoids. Food Funct 1(1):15–31PubMedGoogle Scholar
  49. Pierpaoli C, Jezzard P, Basser PJ, Barnett A, di Chiro G (1996) Diffusion tensor MR imaging of the human brain. Radiology 201(3):637–648PubMedGoogle Scholar
  50. Prakash KG, Bannur BM, Chavan MD, Saniya K, Sailesh KS, Rajagopalan A (2016) Neuroanatomical changes in Parkinson's disease in relation to cognition: an update. J Adv Pharm Technol Res 7(4):123–126PubMedPubMedCentralGoogle Scholar
  51. Rizek P, Kumar N, Jog MS (2016) An update on the diagnosis and treatment of Parkinson disease. CMAJ 188(16):1157–1165PubMedPubMedCentralGoogle Scholar
  52. Rolheiser TM, Fulton HG, Good KP, Fisk JD, McKelvey JR, Scherfler C, Khan NM, Leslie RA, Robertson HA (2011) Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson’s disease. J Neurol 258(7):1254–1260PubMedGoogle Scholar
  53. Rovaris M, Filippi M (2007) Diffusion tensor MRI in multiple sclerosis. J Neuroimaging 17(Suppl 1):27S–30SPubMedGoogle Scholar
  54. Schintu N, Frau L, Ibba M, Garau A, Carboni E, Carta AR (2009) Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson’s disease. Neurotox Res 16(2):127–139PubMedGoogle Scholar
  55. Schwarz ST, Abaei M, Gontu V, Morgan PS, Bajaj N, Auer DP (2013) Diffusion tensor imaging of nigral degeneration in Parkinson’s disease: a region-of-interest and voxel-based study at 3 T and systematic review with meta-analysis. Neuroimage Clin 3:481–488PubMedPubMedCentralGoogle Scholar
  56. Sgado P, Viaggi C et al (2011) Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration. Neurotox Res 20(2):170–181PubMedGoogle Scholar
  57. Sierra A, Laitinen T, Lehtimäki K, Rieppo L, Pitkänen A, Gröhn O (2011) Diffusion tensor MRI with tract-based spatial statistics and histology reveals undiscovered lesioned areas in kainate model of epilepsy in rat. Brain Struct Funct 216(2):123–135PubMedGoogle Scholar
  58. Smith SM (2002) Fast robust automated brain extraction. Hum Brain Mapp 17(3):143–155Google Scholar
  59. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, Watkins KE, Ciccarelli O, Cader MZ, Matthews PM, Behrens TEJ (2006) Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 31(4):1487–1505Google Scholar
  60. Sonsalla PK, Jochnowitz ND, Zeevalk GD, Oostveen JA, Hall ED (1996) Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res 738(1):172–175PubMedGoogle Scholar
  61. Suidan GL, Duerschmied D, Dillon GM, Vanderhorst V, Hampton TG, Wong SL, Voorhees JR, Wagner DD (2013) Lack of tryptophan hydroxylase-1 in mice results in gait abnormalities. PLoS One 8(3):e59032PubMedPubMedCentralGoogle Scholar
  62. Tansey MG, McCoy MK, Frank-Cannon TC (2007) Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208(1):1–25PubMedPubMedCentralGoogle Scholar
  63. Tavassoly O, Lee JS (2012) Methamphetamine binds to alpha-synuclein and causes a conformational change which can be detected by nanopore analysis. FEBS Lett 586(19):3222–3228PubMedGoogle Scholar
  64. Thomas DM, Kuhn DM (2005) Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J Neurochem 92(4):790–797PubMedGoogle Scholar
  65. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Lee JY, Toga AW, Ling W, London ED (2004) Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24(26):6028–6036PubMedPubMedCentralGoogle Scholar
  66. Tieu K (2011) A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harb Perspect Med 1(1):a009316PubMedPubMedCentralGoogle Scholar
  67. Tillerson JL, Miller GW (2003) Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism. J Neurosci Methods 123(2):189–200PubMedGoogle Scholar
  68. Vaillancourt DE, Spraker MB, Prodoehl J, Abraham I, Corcos DM, Zhou XJ, Comella CL, Little DM (2009) High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 72(16):1378–1384PubMedPubMedCentralGoogle Scholar
  69. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J (2001) Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21(23):9414–9418PubMedPubMedCentralGoogle Scholar
  70. Volkow ND, Wang GJ, Smith L, Fowler JS, Telang F, Logan J, Tomasi D (2015) Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release. Neuroimage 121:20–28PubMedGoogle Scholar
  71. Walsh SL, Wagner GC (1992) Motor impairments after methamphetamine-induced neurotoxicity in the rat. J Pharmacol Exp Ther 263(2):617–626PubMedGoogle Scholar
  72. Wang JJ, Lin WY, Lu CS, Weng YH, Ng SH, Wang CH, Liu HL, Hsieh RH, Wan YL, Wai YY (2011) Parkinson disease: diagnostic utility of diffusion kurtosis imaging. Radiology 261(1):210–217PubMedGoogle Scholar
  73. Wu XF, Wang AF, Chen L, Huang EP, Xie WB, Liu C, Huang WY, Chen CX, Qiu PM, Wang HJ (2014) S-Nitrosylating protein disulphide isomerase mediates alpha-synuclein aggregation caused by methamphetamine exposure in PC12 cells. Toxicol Lett 230(1):19–27PubMedGoogle Scholar
  74. Zhu JP, Xu W et al (2006) Methamphetamine-induced striatal apoptosis in the mouse brain: comparison of a binge to an acute bolus drug administration. Neurotoxicology 27(1):131–136PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmacology, Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  2. 2.Applied Neuroscience Research Group, CEITEC - Central European Institute of TechnologyMasaryk UniversityBrnoCzech Republic
  3. 3.Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  4. 4.Institute of Scientific Instruments of the Czech Academy of SciencesBrnoCzech Republic
  5. 5.Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical CentreUniversity of SzegedSzegedHungary
  6. 6.Central European Institute of Technology CEITEC, Neuroscience CentreMasaryk UniversityBrnoCzech Republic
  7. 7.Department of Pharmacology and ToxicologyNational Institute of Pharmaceutical Education and Research (NIPER), AhmedabadGandhinagarIndia

Personalised recommendations